Table 1.
Subject Demographics and Characteristics
| Demographics and Characteristics | Number of subjects = 94 N (%) | |
|---|---|---|
| Age at Diagnosis, years |
Mean±SD: 53.39±11.8 Minimum: 30 Maximum: 82 |
|
| < 45 | 24 (25.53) | |
| 45 – 54 | 27 (28.72) | |
| 55 – 64 | 25 (26.59) | |
| 65+ | 18 (19.15) | |
| Ethnicity | ||
| Caucasian | 75 (79.78) | |
| African American | 16 (17.02) | |
| Asian /Pacific Islander | 2 ( 2.13) | |
| Hispanic | 1 (1.06) | |
| Side Involved | ||
| Right | 52 (55.32) | |
| Left | 42 (44.68) | |
| Hand Dominance | ||
| Right | 85 (90.42) | |
| Left | 9 (9.57) | |
| Involved Side to Hand Dominance | ||
| Ipsilateral side | 55 (58.51) | |
| Contralateral side | 39 (41.49) | |
| Body Mass Index, Baseline, kg/m2 |
Mean±SD: 27.16±6.54 Minimum: 19.1 Maximum: 55.6 |
|
| Normal | 18.5 – 24.9 | 43 (45.74) |
| Overweight | 25 – 29.9 | 32 (34.04) |
| Obese | ≥ 30 | 19 (20.21) |
| Type of Breast Cancer | ||
| Ductal carcinoma-in-situ (DCIS) | 11 (11.70) | |
| Invasive Ductal Carcinoma (IDC) | 44 (46.81) | |
| DCIS & IDC | 31 (32.98) | |
| Other | 8 (8.51) | |
| Stage of Breast Cancer | ||
| 0 | 11 (11.70) | |
| I | 40 (42.55) | |
| II | 30 (31.91) | |
| III | 13 (13.83) | |
| Lymph Node Dissection | ||
| None | 8 (8.51) | |
| ALND | 66 (70.21) | |
| SLNB | 20 (21.28) | |
| Number of Lymph Nodes Sampled |
Mean±SD:12.60±9.78 Minimum: 0 Maximum: 48 |
|
| 0 | 8 (8.51) | |
| 1–3 | 15 (15.96) | |
| 4 – 20 | 56 (59.57) | |
| > 20 | 15 (15.96) | |
| Number of Positive Lymph Nodes |
Mean±SD: 1.40±3.53 Minimum: 0 Maximum: 28 |
|
| 0 | 60 (63.83) | |
| 1 – 3 | 23 (24.47) | |
| > 3 | 11 (11.70) | |
| Surgery | ||
| Breast Conservation Therapy (BCT) | 41 (43.62) | |
| Modified Radical Mastectomy (MRM) | 50† (53.19) | |
| Simple Mastectomy | 3† (3.19) | |
| Reconstruction (N=53)† | †note: N = sum of MRM + Simple mastectomy | |
| No | 23 (43.40) | |
| Yes | 30 (56.60) | |
| ChemotherapyTherapy | ||
| No | 37 (39.36) | |
| Yes | 57 (60.64) | |
| Hormone Therapy | ||
| No | 27 (28.72) | |
| Yes | 67 (71.28) | |
| AI | 15 | |
| SERM | 51 | |
| Other | 1 | |
| Immunotherapy | ||
| No | 28 (29.79) | |
| Yes | 66 (70.21) | |
| Radiation Therapy | ||
| No | 30 (31.91) | |
| Yes | 64 (68.09) | |
Abbreviations: ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; AI, aromatase inhibitor; SERM, selective estrogen receptor modulator